TY - JOUR ID - TI - Impact of Chronic Hepatitis B Virus Infection on Bone Mineral Density AU - Istabraq A. Al-Husseiny, Maysaa K. Al-Malkey, Maitham A. Al-Sammak1, Faheema J. Abo-Alhur PY - 2020 VL - 17 IS - 3 SP - 292 EP - 296 JO - Medical Journal of Babylon مجلة بابل الطبية SN - 1812156X 23126760 AB - Background: Chronic hepatitis B virus (HBV) infection is a common health problem that has a worldwide distribution. Apart from the directeffect of the virus on the liver, there are many extrahepatic manifestations among which the probable effect on bone turnover associated withlow bone mineral density (BMD). Objectives: This study aimed to determine the association between treated and untreated chronic HBVinfection with BMD. Methods: This is a cross‑sectional study which included a total of 48 patients with chronic HBV (28 patients treatedwith tenofovir‑disoproxil‑fumarate [TDF] antiviral drug and 20 patients have not yet started treatment). Other age‑ and sex‑matched 30apparently healthy individuals were recruited to represent the healthy controls. BMD was measured using dual‑energy X‑ray absorptiometryon the anteroposterior lumbar spine (L1–L4 spine) views, from which T‑score was calculated. Liver function tests were also evaluated fromserum samples. Results: Treated patients showed a lower T‑score (−0.48 ± 0.72) than either healthy individuals (1.08 ± 0.84) or untreatedpatients (0.78 ± 0.51), with highly significant differences. In multivariate regression, only disease duration (adjusted odds ratio [OR] = 9.71,95% confidence interval [CI] = 4.8–16.68) and TDF treatment (adjusted OR = 6.4, 95% CI = 4.18–97.05) were significantly associated withBMD. Conclusions: Prolonged use of TDF in the treatment of HBV infection can significantly reduce BMD. Moreover, BMD can also beinversely affected in long‑standing HBV, regardless of treatment regimen.

ER -